Systems and Procedure Packs: Assembly Person Status and Double CHRN Risk

This article is number 09 in Volume 1, Regulatory Framework and Fundamentals, of the fifty-part series on medical device registration in Switzerland. Together with the other nine articles in this volume it forms a complete deliverable on this topic. The publication timestamp, article number, article title and unique URL are listed in the table below.

1. Key takeaways

The assembly person of systems and procedure packs (SPPP) is an independent responsible entity, not a variety of distribution activity. MedDO Art. 11 lists the assembly person separately, Art. 51(5) applies the Swiss authorised representative requirements mutatis mutandis to foreign assembly persons, Art. 55(5) requires registration of name and contact address within 3 months of first placing on the market, together with representative details where one is needed, and Art. 108 brings devices, systems and procedure packs alike into the swissdamed registration obligation. When one entity acts both as representative and as importer, the two roles correspond to different registration records, and as a practical estimate two CHRNs must be obtained separately. Mapping the roles before the first pack leaves the factory avoids the most common scheduling failure in SPPP projects.

2. Legal basis

Verification entry points: MedDO Article 11 (SPPP) and Article 55 (CHRN), together with the Swissmedic FAQ Notifications (BW630_30_009e_MB, PDF, 01.07.2026). These sources establish both the substantive duties of the assembly person and the administrative practice for registration, which is where the double-role questions most often need to be resolved against documented guidance rather than assumption.

3. Expert insights

1. The assembly person is a question of entity status, not logistics. Art. 11 defines the assembly person for systems and procedure packs, and Art. 51(5) applies the CH-REP mandate requirements to foreign assembly persons. Conclusion: treating pack assembly as an extension of warehousing or distribution omits two steps — entity registration and representative appointment — both of which fall before placing on the market. The counterpoint: some companies skip the assembly person duties on the argument that all components are already compliant; that argument does not stand once Art. 11 lists the assembly person as a separate entity, because the duties attach to the act of assembly itself rather than to the compliance status of the components.
2. The double CHRN risk arises from role stacking. When the same company acts both as CH-REP and as importer, the two roles draw their obligations from different sources in MedDO (Art. 51 and Art. 53). Conclusion: different roles correspond to different registration records, and as a practical estimate a CHRN must be obtained separately for each; the EU SRN cannot substitute for the CHRN. The trade-off: separate registration raises maintenance costs, but it keeps the boundary of obligations clear, so that at an inspection the records for each role can be retrieved without cross-contamination. A written role matrix inside the quality system is the standard tool for documenting this split.
3. Fees and vigilance are aggregated at the entity level. Device registration fees are aggregated at the manufacturer/SPPP level rather than the CH-REP level, with a cap of CHF 10,000 per manufacturer/SPPP per year (the first UDI-DI at CHF 200 and each additional one in the same year at CHF 20); Art. 66(1) provides that assembly persons placing systems or procedure packs on the Swiss market must report serious incidents and field safety corrective actions. Conclusion: SPPP stands equal to the manufacturer on fees and vigilance; being a pack does not lighten the duties.

4. Practical recommendations

1. Complete the entity characterisation before placing on the market: confirm whether the activity constitutes assembly under Art. 11, and arrange the CH-REP mandate accordingly (Art. 51(5)).
2. For first placing of systems or procedure packs, complete registration of name, contact address and representative details under Art. 55(5) within 3 months.
3. Where roles are stacked, register and maintain CHRNs separately by role and never merge them into one record (practical estimate).
4. Budget registration fees independently at the SPPP level, observing the annual cap of CHF 10,000.
5. In the vigilance process, state the reporting responsibility of the assembly person (Art. 66(1)) and set out the division of duties with component manufacturers in a written agreement.

5. Verification checklist

• □ Whether the activity constitutes assembly under Art. 11 has been confirmed in writing
• □ The foreign assembly person has completed the CH-REP mandate under Art. 51(5)
• □ Name, contact address and representative details under Art. 55(5) were registered within 3 months
• □ Systems and procedure packs bear no conformity mark (Art. 13(2))
• □ Where roles are stacked, registrations are separated by role (practical estimate: two CHRNs)
• □ Vigilance reporting responsibility is divided in writing between the assembly person and component manufacturers

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers and economic operators entering the Swiss market with end-to-end Swissmedic registration and compliance services, including assembly person characterisation for systems and procedure packs, CH-REP mandates for foreign assemblers, Art. 55(5) registration within the statutory deadline, role-stacked CHRN management, and SPPP fee modelling against the annual cap. For tailored guidance on your product portfolio, contact info@grzanglobal.com.